Business Context and Reporting Period
Company: Virtu Financial, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2017
Event: Entry into a Material Definitive Agreement to acquire KCG Holdings, Inc. (the "Target").
On April 20, 2017, Virtu Financial entered into an Agreement and Plan of Merger to acquire KCG Holdings, Inc. via a merger with a wholly-owned subsidiary. The transaction is subject to customary closing conditions, including stockholder approval, regulatory approvals, and the absence of a material adverse effect.
Key Financial Metrics and Transaction Terms
Merger Consideration:
- Cash Price: $20.00 per share of KCG Holdings Class A common stock.
- Equity/Debt Financing: The transaction will be financed through new equity issuances and debt financing.
Equity Financing Details:
- Temasek Investment: Issuance of 8,012,821 shares at $15.60 per share.
- North Island Holdings (NIH) Investment: Issuance of 40,064,103 shares at $15.60 per share.
- Total Equity Raised (Agreed): Approximately $768.6 million (based on share counts and price).
Debt Financing Details:
- Term Loan Facilities: Up to $825.0 million in senior secured term B loans.
- Bridge Loans/Notes: Up to $825.0 million in senior secured second lien notes or bridge loans (if notes are not issued).
Termination Fee:
- Amount: $45,000,000 payable by the Target to Virtu Financial under specific termination scenarios (e.g., board recommendation change, failure to convene stockholder meeting, or entering a competing proposal within 12 months).
Financial Performance Metrics: The filing text does not provide revenue, profit, cash flow, margins, or existing debt levels for the reporting period. This document focuses solely on the transaction structure.
Material Changes and Agreements
Material Definitive Agreements:
- Merger Agreement: Establishes the terms for the acquisition of KCG Holdings, Inc.
- Voting Agreement: Jefferies LLC (holding 24.5% of Target stock) agreed to vote in favor of the merger.
- Investment Agreements: Executed with Temasek and NIH to fund the transaction.
- Stockholders Agreement: Defines governance rights, including director nominations for NIH and observer rights for Temasek.
- Registration Rights Agreement: Amended to include NIH and Temasek with demand and piggyback registration rights.
Conditions to Closing:
- Approval by holders of a majority of Target Class A Common Stock.
- Expiration of Hart-Scott-Rodino waiting periods and receipt of other regulatory approvals.
- Passing of 20 calendar days from the mailing of the Information Statement to Virtu stockholders.
- Termination date set for January 31, 2018, if the merger is not consummated.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- The Company intends to use reasonable best efforts to consummate the equity and debt financing.
- The Merger is not subject to a financing condition, though financing is required to close.
- Forward-looking statements regarding the completion of the merger and realization of synergies are subject to significant risks.
Risks and Contingencies:
- Transaction Risk: The merger may not be completed timely or at all.
- Integration Risk: Potential inability to successfully implement integration strategies or realize anticipated synergies and cost reductions.
- Operational Disruption: Uncertainty may disrupt business relationships with employees, partners, or governmental entities prior to closing.
- Regulatory Risk: Failure to obtain necessary antitrust or governmental approvals.
Key Facts for Investor Verification
- Acquisition Price: Verify the total enterprise value of KCG Holdings based on the $20.00 per share cash offer and outstanding share count.
- Financing Structure: Confirm the final mix of debt and equity utilized, specifically the issuance of ~48 million new shares to Temasek and NIH at $15.60/share.
- Dilution Impact: Assess the dilution effect of the new equity issuance on existing shareholders.
- Regulatory Approval: Monitor the status of Hart-Scott-Rodino and other antitrust approvals required for closing.
- Termination Fee: Note the $45 million fee payable by the Target if the deal fails under specific conditions.
- Board Composition: Verify the new board structure, including NIH's right to nominate up to two directors and Temasek's observer rights.